Limits...
Maintenance of Chronic Fatigue Syndrome (CFS) in Young CFS Patients Is Associated with the 5-HTTLPR and SNP rs25531 A > G Genotype.

Meyer B, Nguyen CB, Moen A, Fagermoen E, Sulheim D, Nilsen H, Wyller VB, Gjerstad J - PLoS ONE (2015)

Bottom Line: Earlier studies have shown that genetic variability in the SLC6A4 gene encoding the serotonin transporter (5-HTT) may be important for the re-uptake of serotonin (5-HT) in the central nervous system.All 120 patients were recruited from The Department of Paediatrics at Oslo University Hospital, Norway, a national referral center for young CFS patients (12-18 years).Main outcomes were number of steps per day obtained by an accelerometer and disability scored by the Functional Disability Inventory (FDI).

View Article: PubMed Central - PubMed

Affiliation: Dept. of Paediatrics, Akershus University Hospital, Oslo, Norway.

ABSTRACT
Earlier studies have shown that genetic variability in the SLC6A4 gene encoding the serotonin transporter (5-HTT) may be important for the re-uptake of serotonin (5-HT) in the central nervous system. In the present study we investigated how the 5-HTT genotype i.e. the short (S) versus long (L) 5-HTTLPR allele and the SNP rs25531 A > G affect the physical and psychosocial functioning in patients with chronic fatigue syndrome (CFS). All 120 patients were recruited from The Department of Paediatrics at Oslo University Hospital, Norway, a national referral center for young CFS patients (12-18 years). Main outcomes were number of steps per day obtained by an accelerometer and disability scored by the Functional Disability Inventory (FDI). Patients with the 5-HTT SS or SLG genotype had a significantly lower number of steps per day than patients with the 5-HTT LALG, SLA or LALA genotype. Patients with the 5-HTT SS or SLG genotype also had a significantly higher FDI score than patients with the 5-HTT LALG, SLA or LALA genotype. Thus, CFS patients with the 5-HTT SS or SLG genotype had worse 30 weeks outcome than CFS patients with the 5-HTT LALG, SLA or LALA genotype. The present study suggests that the 5-HTT genotype may be a factor that contributes to maintenance of CFS.

No MeSH data available.


Related in: MedlinePlus

Role of polymorphisms in the 5-HTT promotor region.A) The 5-HTT short (S) allele consists of 14 repeats at 22 bp while the long (L) allele consists of 16 repeats and a possible A to G SNP. AP2 is a transcription inhibitor found to bind the sequence if a G substitution is present [5]. B) Five possible allele combinations ranged by their predicted rate of transcription. Frequency of the allele combinations in the Caucasian population: SS: 20%, SLG: 4%, LALG: 5%, SLA: 41% and LALA: 26% [6]. A: adenosine, G: guanosine, AP2: activating enhancer-binding protein. C) 5-HTT mRNA in blood in the CFS patients.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608737&req=5

pone.0140883.g001: Role of polymorphisms in the 5-HTT promotor region.A) The 5-HTT short (S) allele consists of 14 repeats at 22 bp while the long (L) allele consists of 16 repeats and a possible A to G SNP. AP2 is a transcription inhibitor found to bind the sequence if a G substitution is present [5]. B) Five possible allele combinations ranged by their predicted rate of transcription. Frequency of the allele combinations in the Caucasian population: SS: 20%, SLG: 4%, LALG: 5%, SLA: 41% and LALA: 26% [6]. A: adenosine, G: guanosine, AP2: activating enhancer-binding protein. C) 5-HTT mRNA in blood in the CFS patients.

Mentions: In total 86 females and 34 males with CFS were included in the present study. As expected, the patients were less active than the 38 individuals in the matched control group (patients; 4662 ± 220 number of steps per day and 23 ± 0,84 in FDI score; controls 11293 ± 603 number of steps per day and 1.3 ± 0.46 in FDI score). A weak association between the predicted transcription rates and the 5-HTT mRNA expression in blood in the CFS patients (linear regression; beta = 0.10, p = 0.045) was observed (Fig 1A, 1B and 1C).


Maintenance of Chronic Fatigue Syndrome (CFS) in Young CFS Patients Is Associated with the 5-HTTLPR and SNP rs25531 A > G Genotype.

Meyer B, Nguyen CB, Moen A, Fagermoen E, Sulheim D, Nilsen H, Wyller VB, Gjerstad J - PLoS ONE (2015)

Role of polymorphisms in the 5-HTT promotor region.A) The 5-HTT short (S) allele consists of 14 repeats at 22 bp while the long (L) allele consists of 16 repeats and a possible A to G SNP. AP2 is a transcription inhibitor found to bind the sequence if a G substitution is present [5]. B) Five possible allele combinations ranged by their predicted rate of transcription. Frequency of the allele combinations in the Caucasian population: SS: 20%, SLG: 4%, LALG: 5%, SLA: 41% and LALA: 26% [6]. A: adenosine, G: guanosine, AP2: activating enhancer-binding protein. C) 5-HTT mRNA in blood in the CFS patients.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608737&req=5

pone.0140883.g001: Role of polymorphisms in the 5-HTT promotor region.A) The 5-HTT short (S) allele consists of 14 repeats at 22 bp while the long (L) allele consists of 16 repeats and a possible A to G SNP. AP2 is a transcription inhibitor found to bind the sequence if a G substitution is present [5]. B) Five possible allele combinations ranged by their predicted rate of transcription. Frequency of the allele combinations in the Caucasian population: SS: 20%, SLG: 4%, LALG: 5%, SLA: 41% and LALA: 26% [6]. A: adenosine, G: guanosine, AP2: activating enhancer-binding protein. C) 5-HTT mRNA in blood in the CFS patients.
Mentions: In total 86 females and 34 males with CFS were included in the present study. As expected, the patients were less active than the 38 individuals in the matched control group (patients; 4662 ± 220 number of steps per day and 23 ± 0,84 in FDI score; controls 11293 ± 603 number of steps per day and 1.3 ± 0.46 in FDI score). A weak association between the predicted transcription rates and the 5-HTT mRNA expression in blood in the CFS patients (linear regression; beta = 0.10, p = 0.045) was observed (Fig 1A, 1B and 1C).

Bottom Line: Earlier studies have shown that genetic variability in the SLC6A4 gene encoding the serotonin transporter (5-HTT) may be important for the re-uptake of serotonin (5-HT) in the central nervous system.All 120 patients were recruited from The Department of Paediatrics at Oslo University Hospital, Norway, a national referral center for young CFS patients (12-18 years).Main outcomes were number of steps per day obtained by an accelerometer and disability scored by the Functional Disability Inventory (FDI).

View Article: PubMed Central - PubMed

Affiliation: Dept. of Paediatrics, Akershus University Hospital, Oslo, Norway.

ABSTRACT
Earlier studies have shown that genetic variability in the SLC6A4 gene encoding the serotonin transporter (5-HTT) may be important for the re-uptake of serotonin (5-HT) in the central nervous system. In the present study we investigated how the 5-HTT genotype i.e. the short (S) versus long (L) 5-HTTLPR allele and the SNP rs25531 A > G affect the physical and psychosocial functioning in patients with chronic fatigue syndrome (CFS). All 120 patients were recruited from The Department of Paediatrics at Oslo University Hospital, Norway, a national referral center for young CFS patients (12-18 years). Main outcomes were number of steps per day obtained by an accelerometer and disability scored by the Functional Disability Inventory (FDI). Patients with the 5-HTT SS or SLG genotype had a significantly lower number of steps per day than patients with the 5-HTT LALG, SLA or LALA genotype. Patients with the 5-HTT SS or SLG genotype also had a significantly higher FDI score than patients with the 5-HTT LALG, SLA or LALA genotype. Thus, CFS patients with the 5-HTT SS or SLG genotype had worse 30 weeks outcome than CFS patients with the 5-HTT LALG, SLA or LALA genotype. The present study suggests that the 5-HTT genotype may be a factor that contributes to maintenance of CFS.

No MeSH data available.


Related in: MedlinePlus